Beta-blockers are attractive for treating hypertension to prevent heart failure development and reverse established left ventricular dysfunction, with non-selective agents potentially offering greater anti-adrenergic effects.
Hypertension is a major risk factor for the development of heart failure. Mechanisms which maintain normal function in the short term in the pressure overloaded heart have longer term deleterious effects. These include left ventricular (LV) hypertrophy and chronic activation of the adrenergic and renin-angiotensin systems. beta-Blocking agents are capable of blocking the adrenergic system and, to some extent, the renin-angiotensin system. They are therefore attractive in treating hypertension, both for preventing the development of abnormalities and for reversing established LV dysfunction and hypertrophy. Trials in heart failure have shown that these agents prevent progressive myocardial dysfunction, prevent and reverse remodelling and improve intrinsic systolic function. Non-selective beta-blocking agents appear to offer greater anti-adrenergic effects than selective ones. However, more research is needed, including direct comparisons of different agents.
No takes yet. Share an insight, caveat, or question.
Michael R. Bristow (1999) conducted a review in Hypertension and Heart Failure. Beta-blocking agents was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: